Skip to main content
    C

    CONMED Corporation (CNMD)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NYSE

    $49.35
    -1.24 (-2.45%)

    Market Cap: $1.51B

    Last updated: Nov 17, 2026 at 11:04 AM ET

    CONMED Corporation (CNMD) Earnings: Report Dates and Results

    Updated Oct 28, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    CONMED (CNMD) is expected to report earnings on Jan 26, 2027. In the quarter ended Sep 30, 2026, CONMED reported EPS of $1.04, above the $1.00 estimate. It beat the EPS estimate in each of the last 11 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    88%(35/40)
    Avg Surprise
    +15.39%
    Streak
    11 Q

    Upcoming Estimates

    Reports Jan 26, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$1.29
    Range$1.23 - $1.33
    9 analysts
    Revenue Consensus
    $373.88M
    Range$357.99M - $385.35M
    9 analysts
    Reports Apr 27, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.98
    Range$0.90 - $1.10
    5 analysts
    EPS Revisions
    4
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$0.97+0.8%
    60d ago$0.97+0.8%
    30d ago$0.97+0.8%
    7d ago$0.97+0.8%
    Current$0.98
    Revenue Consensus
    $329.30M
    Range$325.49M - $333.12M
    2 analysts

    Next Report

    CNMD has an expected report date of Jan 26, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 9.8% below the $1.43 reported for the quarter ended Dec 31, 2025.

    CNMD Earnings Call

    The latest CNMD earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, CNMD beat 35, missed 3 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $335.56M, down 0.7% from $337.93M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$1.04$1.00$0.99 - $1.02+4.00%Beat-3.7%7N/AOct 28, 2026$335.56M
    Jun 30, 2026$1.38$1.10$1.07 - $1.12+25.45%Beat+20.0%71 up, 0 downJul 29, 2026$343.49M
    Mar 31, 2026$0.89$0.82$0.81 - $0.83+8.54%Beat-6.3%50 up, 3 downApr 29, 2026$317.05M
    Dec 31, 2025$1.43$1.32$1.31 - $1.33+8.33%Beat+6.7%60 up, 0 downJan 28, 2026$373.20M
    Sep 30, 2025$1.08$1.05$1.04 - $1.06+2.86%Beat+2.9%64 up, 0 downNov 5, 2025$337.93M
    Jun 30, 2025$1.15$1.12$1.10 - $1.14+2.68%Beat+17.3%67 up, 0 downJul 30, 2025$342.35M
    Mar 31, 2025$0.95$0.81$0.80 - $0.83+17.28%Beat+20.3%70 up, 5 downApr 30, 2025$321.26M
    Dec 31, 2024$1.34$1.20$1.17 - $1.21+11.67%Beat+26.4%70 up, 1 downFeb 5, 2025$345.94M
    Sep 30, 2024$1.05$1.00$0.98 - $1.01+5.00%Beat+16.7%82 up, 0 downOct 30, 2024$316.70M
    Jun 30, 2024$0.98$0.91$0.88 - $0.99+7.69%Beat+18.1%80 up, 1 downJul 31, 2024$332.10M
    Mar 31, 2024$0.79$0.74$0.73 - $0.74+6.76%Beat+19.7%80 up, 0 downApr 24, 2024$312.27M
    Dec 31, 2023$1.06$1.11$1.10 - $1.12-4.50%Miss+152.4%80 up, 0 downJan 31, 2024$327.05M
    Sep 30, 2023$0.90$0.83$0.82 - $0.84+8.43%Beat+16.9%80 up, 0 downOct 25, 2023$304.58M
    Jun 30, 2023$0.83$0.79$0.78 - $0.81+5.06%Beat+9.2%91 up, 0 downJul 26, 2023$317.65M
    Mar 31, 2023$0.66$0.60$0.58 - $0.61+10.00%Beat-5.7%80 up, 0 downApr 26, 2023$295.47M
    Dec 31, 2022$0.42$0.90$0.78 - $1.03-53.33%Miss-60.7%70 up, 0 downFeb 2, 2023$250.87M
    Sep 30, 2022$0.77$0.75$0.72 - $0.78+2.67%Beat-3.8%70 up, 1 downOct 26, 2022$275.09M
    Jun 30, 2022$0.76$0.75$0.69 - $0.83+1.33%Beat+7.0%60 up, 1 downJul 27, 2022$277.19M
    Mar 31, 2022$0.70$0.62$0.55 - $0.65+12.90%Beat+11.1%60 up, 0 downMay 4, 2022$242.33M
    Dec 31, 2021$1.07$1.03N/A+3.88%Beat+27.4%60 up, 0 downJan 26, 2022$273.97M
    Sep 30, 2021$0.80$0.75$0.67 - $0.81+6.67%Beat-9.1%8N/AOct 27, 2021$248.83M
    Jun 30, 2021$0.71$0.62$0.59 - $0.65+14.52%BeatN/A8N/AJul 28, 2021$255.16M
    Mar 31, 2021$0.63$0.44$0.43 - $0.45+43.18%Beat+23.5%6N/AApr 28, 2021$232.68M
    Dec 31, 2020$0.84$0.77$0.70 - $0.93+9.09%Beat-6.7%6N/AJan 27, 2021$252.83M
    Sep 30, 2020$0.88$0.23-$0.09 - $0.45+282.61%Beat+41.9%6N/AOct 28, 2020$237.84M
    Jun 30, 2020-$0.07-$0.95-$1.52 - -$0.69+92.63%Beat-112.5%7N/AJul 29, 2020$157.78M
    Mar 31, 2020$0.51$0.44$0.09 - $0.61+15.91%Beat-10.5%7N/AApr 29, 2020$214.01M
    Dec 31, 2019$0.90$0.89$0.88 - $0.89+1.12%Beat+23.3%7N/AJan 29, 2020$264.87M
    Sep 30, 2019$0.62$0.56$0.54 - $0.58+10.71%Beat+34.8%6N/AOct 30, 2019$233.59M
    Jun 30, 2019$0.56$0.53$0.52 - $0.55+5.66%Beat+21.7%6N/AJul 31, 2019$238.26M
    Mar 31, 2019$0.57$0.54$0.52 - $0.54+5.56%Beat+7.5%5N/AApr 24, 2019$218.38M
    Dec 31, 2018$0.73$0.73$0.72 - $0.740.00%In line+5.8%5N/AJan 22, 2019$242.44M
    Sep 30, 2018$0.46$0.45$0.40 - $0.48+2.22%Beat+9.5%5N/ANov 1, 2018$202.31M
    Jun 30, 2018$0.46$0.45$0.45 - $0.46+2.22%Beat+12.2%4N/AAug 1, 2018$212.82M
    Mar 31, 2018$0.53$0.43$0.42 - $0.46+23.26%Beat+39.5%5N/AApr 25, 2018$202.06M
    Dec 31, 2017$0.69$0.65$0.64 - $0.67+6.15%Beat+27.8%5N/AJan 31, 2018$222.55M
    Sep 30, 2017$0.42$0.41$0.39 - $0.43+2.44%Beat+2.4%6N/ANov 2, 2017$190.12M
    Jun 30, 2017$0.41$0.41$0.39 - $0.420.00%In line+13.9%6N/AJul 26, 2017$197.15M
    Mar 31, 2017$0.38$0.35N/A+8.57%Beat+26.7%N/AN/AApr 26, 2017$186.57M
    Dec 31, 2016$0.54$0.56N/A-3.57%Miss+3.8%N/AN/AFeb 1, 2017$204.09M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $4.61, up 10.8% from the year before. It was $1.61 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$4.61+10.8%
    Dec 31, 2024$4.16+20.6%
    Dec 31, 2023$3.45+30.2%
    Dec 31, 2022$2.65-17.4%
    Dec 31, 2021$3.21+48.6%
    Dec 31, 2020$2.16-18.5%
    Dec 31, 2019$2.65+21.6%
    Dec 31, 2018$2.18+14.7%
    Dec 31, 2017$1.90+18.0%
    Dec 31, 2016$1.61N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,000 words across 11 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,00911
    2026Q2Jun 30, 20266,85910
    2026Q1Mar 31, 20265,4298
    2025Q4Dec 31, 20255,8779
    2025Q3Sep 30, 20254,1569
    2025Q2Jun 30, 20253,7947
    2025Q1Mar 31, 20255,2269
    2024Q4Dec 31, 20246,7399

    2026Q3 Earnings Call

    Opening remarks

    Unidentified Speaker Conference Call Disclaimer Before the conference call begins, let me remind you that during this call, management will be making comments and statements regarding its financial outlook, plans, and objectives. These statements represent forward-looking statements that involve risks and uncertainties as those terms are defined under federal securities laws. Investors are cautioned that any such forward-looking statements are not guarantees of future events, performance, or results. The company's actual results may differ materially from its current expectations. Please refer to the risks and uncertainties disclosed under the forward-looking information in today's press release, as well as the company's SEC filings, for more details on the risks and uncertainties that may cause actual results to differ materially. The company disclaims any obligation to update any forward-looking statements that may be discussed during this call, except as may be required by applicable law. You will also hear management refer to non-GAAP or adjusted measurements during this discussion. While these figures are not a substitute for GAAP measurements, management uses these figures to aid in monitoring the company's ongoing financial performance from quarter to quarter and year to year on a regular basis, and for benchmarking against other medical technology companies. Reconciliations of those non-GAAP financial measures to the most comparable measures calculated and presented in accordance with GAAP are available in the earnings press release on the Investor Relations portion of our website.

    Operator Operator I would now like to turn the call over to Mr. Patrick J. Beyer, ConMed's president and chief executive officer. Please go ahead, sir.

    Patrick J. Beyer President and CEO Thank you, operator, and welcome, everyone, to our third quarter 2026 earnings call. I am joined on the line by John E. Gallagher, our chief financial officer. Let me provide you with a quick agenda for today's call. I will start with a brief overview of our quarterly financial results. Then I will discuss the sales performance in our general and orthopedic surgery product lines, the key product growth drivers within each, and related operational highlights. John will review our financial results in detail along with our guidance for 2026, which we updated in today's press release. I will then share a few closing remarks before we open the call for questions. With that, let's get started with a review of our financial performance in the third quarter. Unless noted otherwise, all sales growth figures discussed are provided on a year-over-year and constant-currency basis. We reported net revenue of $335.6 million in the third quarter. Our net sales decreased 70 basis points on an as-reported basis and 80 basis points on a constant-currency basis. On an organic constant-currency basis, our net revenue increased 6.7% year over year.

    Frequently Asked Questions About CNMD

    When is CONMED's next earnings date?

    CONMED's next earnings report is expected for Jan 26, 2027.

    Did CNMD beat earnings estimates last quarter?

    Yes. CONMED reported EPS of $1.04 for the quarter ended Sep 30, 2026, above the $1.00 estimate, a 4.00% surprise.

    What EPS do analysts expect from CNMD next quarter?

    The consensus EPS estimate for CONMED for the quarter ending Dec 31, 2026 is $1.29 from 9 analysts, with estimates from $1.23 to $1.33.

    How often does CNMD beat earnings estimates?

    CONMED beat the EPS estimate in each of the last 11 quarters, with an average surprise of +9.11%.